Elanco Animal Health (ELAN) Tops Q3 EPS by 4c, Revenues Miss; Offers FY18 EPS Outlook Above Consensus,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Elanco Animal Health Reports Strong Third Quarter Results, Provides Financial Guidance for Full Year 2018
November 6, 2018 6:02 AM ESTThird quarter revenue grew 9 percent to $761.1 million. Revenue, excluding strategic exits, grew 13 percent to $733.4 million; removing the impact of foreign currency exchange rates, growth was 15 percent. Reported net income grew $80.9 million in the third quarter to $60.2 million, which represents $0.16 per diluted share and $0.29 per diluted share on an adjusted basis. Delivered Innovation, including launching Prevacent® PRRS, a swine vaccine, and CorrelinkTM, a nutritional health product for poultry, as well as signing a licensing agreement with Novozymes to... More
